At the 2024 annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Vancouver, Canada, Hélio Tomás, PhD, senior research associate at the Instituto de Biologia Experimental e ...
Panelists discuss how bridging therapy during the CAR T manufacturing waiting period requires careful patient-specific decisions about whether to use chemotherapy, targeted agents, or observation ...
Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen receptor (CAR) T-cell administration in patients with relapsed/refractory ...
The remarkable clinical success of CAR T therapies in blood cancers has validated the promise of engineered cell therapies. But according to Adam Janvier, PhD, head of cell therapy at eXmoor Pharma, ...
The US Food and Drug Administration (FDA) outlined its thinking on what sponsors should consider when submitting premarket applications for chimeric antigen receptor (CAR) T cell products, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results